Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
2 hedge funds and large institutions have $49K invested in Meridian Bioscience Inc in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 212 closing their positions.
99% less funds holding
Funds holding: 218 → 2 (-216)
100% less funds holding in top 10
Funds holding in top 10: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $1.32B → $49K (-$1.32B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 212
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$251M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$165M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$72.2M |
| 4 |
Renaissance Technologies
New York
|
-$69.8M |
| 5 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$64.4M |
VIVO Hedge Fund Activity: Q1 2023 in Review
2 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2023, worth a combined $49K — down 100% from $1.32B a quarter earlier.
Sellers outnumbered buyers: 212 funds closed out of VIVO and 0 opened new positions — a net loss of 212 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $251M sold.
- 2 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2023, down from 218 in Q4 2022.
- Funds reported $49K of Meridian Bioscience Inc stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Meridian Bioscience Inc positions in Q1 2023 and 212 closed out, a net change of -212 holders.
- The largest Meridian Bioscience Inc seller in Q1 2023 was BlackRock, an estimated $251M sold.
Based on aggregated 13F filings for Q1 2023.